Literature DB >> 17074016

Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles.

Jun Dou1, Pengbo Liu, Jing Wang, Xinjian Zhang.   

Abstract

BACKGROUND AND AIMS: The hepatitis C virus (HCV) C region has been reported to have overlapping genes or regions, and may encode a core shadow protein that has a role in HCV self-replication, pathogenesis and carcinogenesis. The aim of this study was to identify the effect of HCV core shadow protein expressed in a human hepatoma (Huh-7) cell line on human gene expression profiles.
METHODS: Recombinants for expression of HCV genotype 1b core shadow protein and genotype 1b core protein were constructed, and an Huh-7 cell line was established that could express the shadow protein and the core protein constitutively. Affymetrix human gene chip, HG-U133 A and B microarray analysis and semiquantitative RT-PCR were employed to identify the expression profiles of two kinds of core proteins in the Huh-7 cell line.
RESULTS: The microarray analysis showed that the core shadow protein caused expression of more genes to be up/down-regulation than the core protein, including signal transduction, protease activity, molecular transport and, particularly, immune responses genes. Surprisingly, the core shadow protein could increase/decrease expression of apoptosis and anti-apoptosis genes simultaneously. The expression profiles of three up-regulated genes were confirmed by semiquantitative RT-PCR, with results similar to the microarray analysis.
CONCLUSIONS: Hepatitis C virus core shadow protein may play an important role in inhibiting or stimulating host cells apoptosis processing and carcinogenesis, which is useful for the understanding of HCV core shadow protein biological functions in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074016     DOI: 10.1111/j.1440-1746.2006.04380.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Identification of immunogenic regions within the alternative reading frame protein of hepatitis C virus (genotype 3).

Authors:  H Qureshi; R Qazi; S Hamid; S A Qureshi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-02-12       Impact factor: 3.267

2.  Genotypic Regulation of Type I Interferon Induction Pathways by Frameshift (F) Proteins of Hepatitis C Virus.

Authors:  Yi-Ting Lai; Yih-Mei Liou; Fu Hsin; Helene Minyi Liu
Journal:  J Virol       Date:  2020-07-16       Impact factor: 5.103

3.  Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.

Authors:  Yunxia Zhang; Jing Wang; Mulan Ren; Miao Li; Dengyu Chen; Junsong Chen; Fangfang Shi; Xiaoying Wang; Jun Dou
Journal:  J Ovarian Res       Date:  2014-01-20       Impact factor: 4.234

4.  Hepatitis C virus core impacts expression of miR122 and miR204 involved in carcinogenic progression via regulation of TGFBRAP1 and HOTTIP expression.

Authors:  Xiaoying Wang; Jiefu Peng; Jing Wang; Miao Li; Di Wu; Songyan Wu; Jipei Liao; Jun Dou
Journal:  Onco Targets Ther       Date:  2018-03-02       Impact factor: 4.147

5.  Inhibition of HCV by the serpin antithrombin III.

Authors:  Mohammed Asmal; Michael Seaman; Wenyu Lin; Raymond T Chung; Norman L Letvin; Ralf Geiben-Lynn
Journal:  Virol J       Date:  2012-10-02       Impact factor: 4.099

6.  Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis.

Authors:  Ming-Ling Chang; Chau-Ting Yeh; Jeng-Chang Chen; Chau-Chun Huang; Shi-Ming Lin; I-Shyan Sheen; Dar-In Tai; Chia-Ming Chu; Wei-Pin Lin; Ming-Yu Chang; Chun-Kai Liang; Cheng-Tang Chiu; Deng-Yn Lin
Journal:  BMC Genomics       Date:  2008-02-29       Impact factor: 3.969

7.  An efficient method for mining cross-timepoint gene regulation sequential patterns from time course gene expression datasets.

Authors:  Chun-Pei Cheng; Yu-Cheng Liu; Yi-Lin Tsai; Vincent S Tseng
Journal:  BMC Bioinformatics       Date:  2013-09-24       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.